Achalasia Type III: Definition, Uses, and Clinical Overview

Posted on February 28, 2026 | by drgastroenterologist

Achalasia Type III Introduction (What it is)

Achalasia Type III is a subtype of achalasia defined by abnormal, spastic contractions in the esophagus.
It describes a specific pattern seen on high-resolution manometry, a test that measures esophageal pressure and motility.
In plain terms, the lower esophageal sphincter does not relax normally, and the esophageal body squeezes in an uncoordinated, high-pressure way.
It is commonly used in gastroenterology to classify achalasia and guide discussions about management options.

Why Achalasia Type III used (Purpose / benefits)

Achalasia is an esophageal motility disorder in which the lower esophageal sphincter (LES)—the valve-like muscle at the gastroesophageal junction—fails to relax appropriately during swallowing, and normal peristalsis (coordinated wave-like contractions that move food) is impaired. Achalasia Type III is used to identify a specific “spastic” phenotype within this broader diagnosis.

The main purpose of labeling Achalasia Type III is to improve diagnostic precision and clinical communication. Different achalasia subtypes can present with overlapping symptoms (for example dysphagia, chest discomfort, regurgitation, weight change), but they may differ in underlying motor patterns and in how clinicians frame therapeutic choices. In practice, the subtype:

Helps standardize interpretation of high-resolution esophageal manometry (HRM) findings using the Chicago Classification framework.
Provides a shared language among gastroenterologists, surgeons, radiologists, and trainees when describing disease behavior.
Supports a more tailored discussion of expected symptom patterns (for example prominent chest pain in some patients) and potential procedural considerations (varies by clinician and case).

This classification does not “treat” the disease on its own. Instead, it organizes physiologic information so that the diagnostic pathway is clearer and the clinical plan can be discussed using consistent terms.

Clinical context (When gastroenterologists or GI clinicians use it)

Achalasia Type III is typically referenced in the following scenarios:

Evaluating persistent dysphagia (difficulty swallowing) to solids and/or liquids with unclear cause.
Investigating non-cardiac chest pain when reflux and cardiac disease have been excluded or are less likely.
Interpreting HRM results after endoscopy (esophagogastroduodenoscopy, EGD) has excluded structural obstruction.
Reviewing a timed barium esophagram (contrast swallow study) that suggests impaired esophageal emptying.
Distinguishing achalasia from other motility disorders such as distal esophageal spasm or esophagogastric junction outflow obstruction (EGJOO).
Planning multidisciplinary conversations (GI, GI surgery, sometimes otolaryngology) about procedural approaches (varies by clinician and case).
Reassessing symptoms after prior intervention for achalasia, when repeat physiology testing is needed.

Contraindications / when it’s NOT ideal

Achalasia Type III is a diagnostic label based on manometric criteria, so “contraindications” mainly relate to when the label may be unreliable or when the typical diagnostic pathway is not the best fit. Situations where it may be less suitable or where alternatives are emphasized include:

Inadequate or uninterpretable manometry (poor catheter position, limited swallows, artifacts, intolerance), making subtype assignment uncertain.
Mechanical obstruction or pseudoachalasia (achalasia-like physiology due to a tumor, stricture, or external compression). In these cases, structural evaluation takes priority.
Marked anatomic distortion (for example large hiatal hernia or altered anatomy after upper GI surgery), which can complicate manometry interpretation (varies by clinician and case).
Medication effects on motility (some agents can influence esophageal pressures), potentially confounding results; clinicians interpret within context.
Acute systemic illness where elective motility testing is deferred until stable.
When symptoms are better explained by another diagnosis (for example prominent heartburn with normal motility may point away from achalasia).

Separately, if the question is “when is a specific therapy not ideal for Achalasia Type III,” the answer depends on local expertise, patient anatomy, comorbidities, and risk tolerance (varies by clinician and case). The subtype informs those conversations but does not dictate a single universal approach.

How it works (Mechanism / physiology)

Achalasia Type III reflects disordered esophageal neuromuscular control. The esophagus normally moves a swallowed bolus by coordinated peristalsis, while the LES relaxes to allow passage into the stomach. In achalasia, inhibitory neurons in the myenteric (Auerbach) plexus are impaired, leading to incomplete LES relaxation and loss of normal peristalsis.

What makes Achalasia Type III distinct is the presence of premature, spastic distal esophageal contractions in addition to impaired LES relaxation. On HRM, this appears as:

Elevated integrated relaxation pressure (IRP): a measure suggesting impaired LES relaxation during swallowing (interpretation depends on the manometry system and protocol).
Premature contractions in the distal esophagus: contractions occur too early or in a discoordinated way rather than as a smooth peristaltic wave.
High-amplitude pressurization may occur, correlating with the “spastic” or “hypercontractile” feel of the disorder.

Relevant anatomy includes the esophageal body (especially the distal smooth muscle segment) and the esophagogastric junction (EGJ), which includes the LES and diaphragmatic crura. Physiologically, the disorder affects bolus transit (movement of food/liquid), predisposes to esophageal retention, and can contribute to symptoms such as dysphagia and regurgitation. Symptom intensity and the relationship between manometric findings and symptoms can vary by individual.

Achalasia is typically chronic unless treated. The manometric pattern can evolve over time, and interpretation is clinical: the subtype supports understanding of physiology, but it is not a direct measure of mucosal injury or cancer risk.

Achalasia Type III Procedure overview (How it’s applied)

Achalasia Type III is not a standalone procedure; it is most often the result of a diagnostic workup, especially HRM. A typical high-level workflow is:

History and physical exam
– Characterize dysphagia (solids, liquids, both), regurgitation, chest pain, weight change, and aspiration symptoms.
– Review medications, prior surgeries, and systemic diseases that can affect motility.
Initial testing (often to rule out structural disease)
– EGD to assess for stricture, ring, tumor, esophagitis, or retained food.
– Biopsies may be taken if clinically indicated.
Imaging/physiology diagnostics
– Timed barium esophagram to evaluate esophageal emptying and morphology (for example dilation, “bird-beak” narrowing).
– High-resolution manometry to measure LES relaxation and esophageal body contraction patterns and assign a subtype (Type I, II, or III).
– Some centers use functional luminal imaging probe (FLIP) during endoscopy to assess EGJ distensibility (availability varies).
Preparation and intervention/testing
– Patients commonly fast before EGD/manometry per institutional protocol (details vary).
– Sedation may be used for EGD; HRM is typically done without sedation.
Immediate checks and follow-up
– Results are interpreted in clinical context, including symptom profile and endoscopic/radiographic findings.
– Follow-up focuses on symptom monitoring and reassessment after any intervention, with additional testing if needed.

Types / variations

Achalasia Type III is best understood within the broader classification of achalasia and related esophageal motility disorders.

Common clinical “types” and variations discussed alongside Achalasia Type III include:

Achalasia subtypes (Chicago Classification)
Type I (classic): absent peristalsis with minimal pressurization.
Type II: absent peristalsis with panesophageal pressurization (uniform pressurization of the esophageal body).
Achalasia Type III: impaired EGJ relaxation plus premature/spastic distal contractions.
Related motility disorders in the differential
Esophagogastric junction outflow obstruction (EGJOO): elevated IRP without meeting full achalasia criteria; may be clinically significant or transient.
Distal esophageal spasm: premature contractions without the classic achalasia pattern of impaired EGJ relaxation meeting achalasia criteria.
Hypercontractile (jackhammer) esophagus: very strong contractions with different manometric features.
Variation by testing platform and protocol
HRM interpretation depends on catheter type, software, patient position (supine vs upright), and local protocol (varies by material and manufacturer).
Adjunct tests (timed barium esophagram, FLIP) may be used differently across institutions.
Variation by clinical course
Some patients present early with prominent chest pain and intermittent dysphagia.
Others present later with more consistent obstruction-type symptoms and retention.

Pros and cons

Pros:

Provides a standardized, physiology-based label for a spastic achalasia pattern.
Helps differentiate achalasia from other causes of dysphagia when combined with EGD and imaging.
Improves team communication across GI, radiology, and surgery.
Supports more tailored discussions of procedural strategies (varies by clinician and case).
Encourages comprehensive evaluation for mimics such as structural obstruction or pseudoachalasia.
Useful for teaching and for framing clinical reasoning in trainees.

Cons:

Depends on test quality and correct interpretation; artifacts can misclassify patterns.
HRM access and expertise can be limited in some settings.
Symptoms do not always correlate neatly with manometric subtype.
The subtype label can be overemphasized if structural causes are not adequately excluded first.
Classification systems evolve, so terminology and thresholds can shift over time.
Not all patients fit cleanly into a single category, especially after prior interventions.

Aftercare & longevity

Because Achalasia Type III is a diagnostic category rather than a treatment, “aftercare” typically refers to follow-up after evaluation and, when chosen, after an intervention aimed at improving esophageal emptying and reducing outflow resistance at the EGJ.

General factors that can influence longer-term outcomes include:

Baseline disease severity and esophageal anatomy, including degree of retention or dilation on imaging.
The chosen intervention and local expertise, including endoscopic and surgical approaches (varies by clinician and case).
Presence of reflux symptoms after interventions that reduce EGJ resistance; follow-up plans often account for gastroesophageal reflux disease (GERD) risk.
Nutrition and eating patterns, since dysphagia can affect intake; teams may involve nutrition services when needed.
Comorbidities that affect swallowing safety (for example neurologic disease) or procedural risk.
Adherence to follow-up, which may include symptom scoring, repeat imaging, endoscopy, or motility testing when clinically indicated.

Longevity of symptom improvement varies. Some patients require reassessment over time for recurrent dysphagia, reflux symptoms, or evolving motility patterns, and the intensity of monitoring differs by case and institution.

Alternatives / comparisons

Achalasia Type III is one part of the diagnostic framework; alternatives and comparisons often relate to (1) alternative diagnoses and (2) alternative management strategies once the diagnosis is established.

High-level comparisons include:

Observation/monitoring vs intervention
Monitoring may be considered when symptoms are mild or when diagnostic uncertainty remains.
Interventions are generally discussed when symptoms are clinically significant or when nutrition/aspiration risk becomes a concern (varies by clinician and case).
Medication vs procedure
Pharmacologic options (for example smooth muscle relaxants) are sometimes discussed for symptom modulation, but durable physiologic correction typically involves endoscopic or surgical approaches (details vary by clinician and case).
Botulinum toxin injection can reduce LES pressure temporarily in some contexts; durability varies.
Endoscopic vs surgical approaches
Options may include pneumatic dilation, laparoscopic Heller myotomy (often with a partial fundoplication), and peroral endoscopic myotomy (POEM).
For Achalasia Type III, clinicians often consider how well a given approach addresses spastic contractions in the esophageal body as well as EGJ outflow resistance (varies by clinician and case).
Barium esophagram vs HRM vs FLIP
Barium studies visualize emptying and anatomy.
HRM defines motility patterns and assigns subtype.
FLIP estimates EGJ distensibility during endoscopy; its role varies by center.

Balanced interpretation is important: each test and approach answers a different clinical question, and choice depends on availability, patient factors, and clinician judgment.

Achalasia Type III Common questions (FAQ)

Q: What symptoms are most associated with Achalasia Type III?
Dysphagia to liquids and solids can occur, along with regurgitation of retained food or saliva. Some patients report chest pain or a squeezing sensation, which can reflect spastic esophageal contractions. Symptom patterns vary and are not specific enough to confirm the subtype without testing.

Q: How is Achalasia Type III diagnosed?
The subtype is primarily diagnosed with high-resolution manometry, which measures pressure patterns during swallowing. Endoscopy is commonly performed to rule out mechanical obstruction, and a barium esophagram may show impaired emptying. Clinicians integrate all findings because no single test fully captures anatomy, mucosa, and motility.

Q: Does Achalasia Type III require endoscopy?
Endoscopy is frequently part of the workup because it helps exclude strictures, tumors, or severe inflammation that can mimic achalasia. It can also identify retained food and assess the esophageal lining. Whether it is required in every pathway varies by clinician and case.

Q: Is sedation or anesthesia used for the key tests?
Endoscopy is often performed with sedation, depending on the setting and patient factors. High-resolution manometry is typically done without sedation because swallowing function needs to be assessed while the patient is awake. Specific protocols differ by institution.

Q: Do patients need to fast before manometry or imaging?
Many centers ask patients to fast for a period before manometry, endoscopy, or barium studies to reduce aspiration risk and improve test quality. The exact fasting duration varies by facility protocol. Instructions are usually provided by the testing unit.

Q: Is Achalasia Type III “more severe” than other types?
“Severity” can mean different things—symptom burden, physiologic abnormality, nutritional impact, or treatment response. Achalasia Type III highlights a spastic contraction pattern, which may be associated with prominent chest pain in some patients. Overall impact varies widely between individuals.

Q: How long do results or symptom improvements last after treatment?
Durability depends on the chosen intervention, the underlying anatomy and physiology, and follow-up care (varies by clinician and case). Some patients have long-lasting improvement, while others experience recurrence and need reassessment. Because achalasia is a chronic motility disorder, periodic follow-up is common.

Q: What are common downsides discussed for procedures used in achalasia?
Potential downsides can include reflux symptoms after therapies that reduce EGJ resistance, need for repeat interventions, and procedure-related risks that vary by approach and patient factors. Teams typically discuss these in a balanced way using the patient’s anatomy and test findings. Risk profiles vary by clinician and case.

Q: How soon can someone return to school or work after diagnostic testing?
After manometry or barium imaging, many people can resume usual activities quickly, depending on how they feel and institutional instructions. After sedated endoscopy, same-day activity restrictions are common due to sedation effects. After therapeutic procedures, recovery time varies by intervention and individual factors.

Q: What does “Type III” change in clinical decision-making?
The subtype provides information about the pattern and location of abnormal contractions, not just whether the LES fails to relax. Clinicians may use this to discuss which interventions are more likely to address both EGJ outflow resistance and spastic distal contractions. The final plan depends on symptoms, comorbidities, anatomy, and local expertise (varies by clinician and case).